Pazianas Michael, van der Geest Stefan, Miller Paul
Nuffield Orthopaedic Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Diseases, The Botnar Research Center, Institute of Musculoskeletal Sciences, Oxford University , Oxford, UK.
HRA Pharma , Paris, France.
Bonekey Rep. 2014 May 7;3:529. doi: 10.1038/bonekey.2014.24. eCollection 2014.
Bisphosphonates (BPs) are bone-avid compounds used as first-line medications for the prevention and treatment of osteoporosis. They are also used in other skeletal pathologies such as Paget's and metastatic bone disease. They effectively reduce osteoclast viability and also activity in the resorptive phase of bone remodelling and help preserve bone micro-architecture, both major determinants of bone strength and ultimately of the susceptibility to fractures. The chemically distinctive structure of each BP used in the clinic determines their unique affinity, distribution/penetration throughout the bone and their individual effects on bone geometry, micro-architecture and composition or what we call 'bone quality'. BPs have no clinically significant anabolic effects. This review will touch upon some of the components of bone quality that could be affected by the administration of BPs.
双膦酸盐(BPs)是亲骨化合物,用作预防和治疗骨质疏松症的一线药物。它们也用于其他骨骼疾病,如佩吉特病和转移性骨病。它们可有效降低破骨细胞的活力,并在骨重塑的吸收阶段发挥作用,有助于保持骨微结构,而骨微结构是骨强度以及最终骨折易感性的两个主要决定因素。临床使用的每种双膦酸盐独特的化学结构决定了它们独特的亲和力、在整个骨骼中的分布/渗透以及它们对骨几何形状、微结构和组成(即我们所说的“骨质量”)的个体影响。双膦酸盐没有临床上显著的合成代谢作用。本综述将探讨可能受双膦酸盐给药影响的一些骨质量成分。